Suven Life Sciences Limited (SUVEN.BO)
INR 142.95
(-0.56%)
INR 142.95
(-0.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 116.92 Million INR | -13.64% |
| 2022 | 135.39 Million INR | 14.31% |
| 2021 | 118.44 Million INR | -12.12% |
| 2020 | 134.78 Million INR | -6.5% |
| 2019 | 144.14 Million INR | -94.77% |
| 2018 | 2.75 Billion INR | -54.98% |
| 2017 | 6.12 Billion INR | 13.82% |
| 2016 | 5.38 Billion INR | 7.75% |
| 2015 | 4.99 Billion INR | -4.1% |
| 2014 | 5.2 Billion INR | 2.07% |
| 2013 | 5.1 Billion INR | 97.88% |
| 2012 | 2.57 Billion INR | 26.29% |
| 2011 | 2.04 Billion INR | 35.75% |
| 2010 | 1.5 Billion INR | 16.33% |
| 2009 | 1.29 Billion INR | -8.18% |
| 2008 | 1.4 Billion INR | 17.38% |
| 2007 | 1.19 Billion INR | 5.93% |
| 2006 | 1.13 Billion INR | 25.69% |
| 2005 | 901.11 Million INR | 36.04% |
| 2004 | 662.4 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 25.72 Million INR | 155.76% |
| 2024 Q1 | 10.06 Million INR | -57.82% |
| 2023 FY | 116.92 Million INR | -13.64% |
| 2023 Q4 | 23.85 Million INR | -2.68% |
| 2023 Q1 | 37.97 Million INR | 45.43% |
| 2023 Q3 | 24.5 Million INR | -19.9% |
| 2023 Q2 | 30.59 Million INR | -19.43% |
| 2022 Q3 | 30.02 Million INR | -31.55% |
| 2022 FY | 135.39 Million INR | 14.31% |
| 2022 Q2 | 43.86 Million INR | 23.94% |
| 2022 Q4 | 26.11 Million INR | -13.03% |
| 2022 Q1 | 35.39 Million INR | -16.16% |
| 2021 Q1 | 20.06 Million INR | 28.84% |
| 2021 FY | 118.44 Million INR | -12.12% |
| 2021 Q4 | 42.21 Million INR | -4.78% |
| 2021 Q3 | 44.32 Million INR | 274.37% |
| 2021 Q2 | 11.84 Million INR | -40.98% |
| 2020 Q1 | 14.28 Million INR | -83.5% |
| 2020 Q2 | 89.79 Million INR | 528.56% |
| 2020 Q3 | 15.13 Million INR | -83.15% |
| 2020 Q4 | 15.57 Million INR | 2.91% |
| 2020 FY | 134.78 Million INR | -6.5% |
| 2019 Q4 | 86.6 Million INR | 212.34% |
| 2019 FY | 144.14 Million INR | -94.77% |
| 2019 Q3 | 27.72 Million INR | 99.86% |
| 2019 Q1 | 15.94 Million INR | -99.56% |
| 2019 Q2 | 13.87 Million INR | -13.02% |
| 2018 Q4 | 3.62 Billion INR | 17094.24% |
| 2018 Q1 | 1.91 Billion INR | 0.0% |
| 2018 Q3 | 21.05 Million INR | -97.65% |
| 2018 Q2 | 895.21 Million INR | -53.29% |
| 2018 FY | 2.75 Billion INR | -54.98% |
| 2017 FY | 6.12 Billion INR | 13.82% |
| 2016 FY | 5.38 Billion INR | 7.75% |
| 2016 Q4 | 1.8 Billion INR | 0.0% |
| 2015 Q3 | 1.12 Billion INR | -3.65% |
| 2015 Q4 | 1.69 Billion INR | 50.55% |
| 2015 FY | 4.99 Billion INR | -4.1% |
| 2015 Q2 | 1.16 Billion INR | 15.63% |
| 2015 Q1 | 1 Billion INR | -8.75% |
| 2014 Q2 | 1.39 Billion INR | -1.2% |
| 2014 Q1 | 1.41 Billion INR | 8.2% |
| 2014 FY | 5.2 Billion INR | 2.07% |
| 2014 Q4 | 1.1 Billion INR | -14.1% |
| 2014 Q3 | 1.28 Billion INR | -7.87% |
| 2013 Q1 | 1.08 Billion INR | 45.47% |
| 2013 Q4 | 1.3 Billion INR | 9.53% |
| 2013 Q3 | 1.19 Billion INR | -21.12% |
| 2013 FY | 5.1 Billion INR | 97.88% |
| 2013 Q2 | 1.51 Billion INR | 39.33% |
| 2012 Q3 | 623.94 Million INR | 24.15% |
| 2012 Q4 | 747.03 Million INR | 19.73% |
| 2012 FY | 2.57 Billion INR | 26.29% |
| 2012 Q1 | 705.27 Million INR | 0.0% |
| 2012 Q2 | 502.59 Million INR | -28.74% |
| 2011 FY | 2.04 Billion INR | 35.75% |
| 2010 FY | 1.5 Billion INR | 16.33% |
| 2009 FY | 1.29 Billion INR | -8.18% |
| 2008 FY | 1.4 Billion INR | 17.38% |
| 2007 FY | 1.19 Billion INR | 5.93% |
| 2006 FY | 1.13 Billion INR | 25.69% |
| 2005 FY | 901.11 Million INR | 36.04% |
| 2004 FY | 662.4 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 99.722% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 97.224% |
| Sigachi Industries Limited | 3.98 Billion INR | 97.069% |
| Bal Pharma Limited | 3.39 Billion INR | 96.553% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 99.087% |
| Medico Remedies Limited | 1.44 Billion INR | 91.932% |
| Lasa Supergenerics Limited | 1.04 Billion INR | 88.793% |
| Venus Remedies Limited | 5.91 Billion INR | 98.023% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | 84.522% |
| Alpa Laboratories Limited | 1.08 Billion INR | 89.247% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 99.306% |
| Shilpa Medicare Limited | 11.51 Billion INR | 98.985% |
| Aarti Drugs Limited | 25.28 Billion INR | 99.538% |
| Lupin Limited | 200.1 Billion INR | 99.942% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.959% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.939% |
| Windlas Biotech Limited | 6.3 Billion INR | 98.147% |
| Eris Lifesciences Limited | 20.09 Billion INR | 99.418% |
| Valiant Laboratories Limited | 1.82 Billion INR | 93.577% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 99.664% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 99.056% |
| Ipca Laboratories Limited | 76.22 Billion INR | 99.847% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 98.482% |
| Achyut Healthcare Limited | 61.36 Million INR | -90.534% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.976% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 97.53% |
| RPG Life Sciences Limited | 5.82 Billion INR | 97.991% |
| Mankind Pharma Limited | 103.34 Billion INR | 99.887% |
| Laurus Labs Limited | 50.01 Billion INR | 99.766% |
| Piramal Pharma Limited | 81.71 Billion INR | 99.857% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 95.49% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 99.89% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 99.809% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 99.901% |
| Unichem Laboratories Limited | 16.57 Billion INR | 99.295% |
| Sequent Scientific Limited | 13.69 Billion INR | 99.146% |
| Novartis India Limited | 3.35 Billion INR | 96.51% |
| Wanbury Limited | 5.75 Billion INR | 97.969% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 98.888% |
| Wockhardt Limited | 27.89 Billion INR | 99.581% |
| Themis Medicare Limited | 3.81 Billion INR | 96.937% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 94.397% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 99.826% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 99.488% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.958% |
| Divi's Laboratories Limited | 78.45 Billion INR | 99.851% |
| NATCO Pharma Limited | 40.02 Billion INR | 99.708% |
| Gufic Biosciences Limited | 8.06 Billion INR | 98.55% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 99.448% |
| Ind-Swift Limited | 5.02 Billion INR | 97.673% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 98.984% |
| FDC Limited | 19.42 Billion INR | 99.398% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | 76.81% |
| Granules India Limited | 45.06 Billion INR | 99.741% |
| Medicamen Biotech Limited | 1.79 Billion INR | 93.479% |
| Alkem Laboratories Limited | 126.67 Billion INR | 99.908% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 99.097% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | 70.794% |
| Brooks Laboratories Limited | 794.86 Million INR | 85.289% |
| Megasoft Limited | 373.95 Million INR | 68.732% |
| ZIM Laboratories Limited | 3.67 Billion INR | 96.818% |
| Strides Pharma Science Limited | 40.51 Billion INR | 99.711% |
| Neuland Laboratories Limited | 15.58 Billion INR | 99.25% |
| Morepen Laboratories Limited | 17.01 Billion INR | 99.313% |
| Hikal Limited | 17.84 Billion INR | 99.345% |
| Indoco Remedies Limited | 17.89 Billion INR | 99.347% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 99.356% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 92.426% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 96.828% |
| Hester Biosciences Limited | 3.04 Billion INR | 96.161% |